Immunoglobulin Market

Executive Summary

Immunoglobulin Market was valued at US $14.80 billion in 2021 and is projected to grow at 7.28% CAGR over the forecast period to reach US $22.57 billion by 2027. Immunoglobulin Market represented US $1.94 billion opportunity over 2019-2021 and estimated to create US $7.77 billion opportunity in 2027 over 2021.

Immunoglobulin from Consainsights analyses the Immunoglobulin Market in the Life Sciences industry over the forecast period to 2027.

Immunoglobulin research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Immunoglobulin segmentation includes Product, Mode of Delivery, Application and Geography.

Based on the Product, the Immunoglobulin analysis covers IgG, IgA, IgM, IgE, IgD.

In Product segment, IgG segment has highest cagr growth of 6.45%.

Based on the Mode of Delivery, the Immunoglobulin analysis covers Intravenous Mode of Delivery, Subcutaneous Mode of Delivery.

In Mode of Delivery segment, Intravenous Mode of Delivery segment has highest cagr growth of 6.45%.

Based on the Application, the Immunoglobulin analysis covers Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Other Applications.

In Application segment, Hypogammaglobulinemia segment has highest cagr growth of 6.45%.

Based on the region, the Immunoglobulin analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Baxter international Inc., CSL Ltd, Grifols SA, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products Inc., Shire (Baxalta), Bayer Healthcare, Takeda Pharmaceutical Company Limited, Bio Products Laboratory, Sanquin Plasma Products BV, Evolve Biologics Inc., GigaGen Inc., Shanghai RAAS Blood Products Co. Ltd, ADMA Biologics Inc., Johnson & Johnson (Omrix Biopharmaceuticals Inc.) and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product

Introduction

In 2021, IgG segment has the highest revenue of US $6.52 billion and is expected to grow at CAGR of 6.45% by 2027 IgG segment has highest cagr growth of 6.45%.

IgG

IgG segment was valued at US $5.66 billion in 2019 and is projected to grow at 6.45% CAGR over the forecast period to reach US $9.93 billion by 2027. IgG segment represented US $0.85 billion opportunity over 2019-2021 and estimated to create US $3.42 billion opportunity in 2027 over 2021.

IgA

IgA segment was valued at US $3.29 billion in 2019 and is projected to grow at 6.45% CAGR over the forecast period to reach US $5.77 billion by 2027. IgA segment represented US $0.50 billion opportunity over 2019-2021 and estimated to create US $1.99 billion opportunity in 2027 over 2021.

IgM

IgM segment was valued at US $2.27 billion in 2019 and is projected to grow at 6.45% CAGR over the forecast period to reach US $3.99 billion by 2027. IgM segment represented US $0.34 billion opportunity over 2019-2021 and estimated to create US $1.37 billion opportunity in 2027 over 2021.

IgE

IgE segment was valued at US $0.71 billion in 2019 and is projected to grow at 6.45% CAGR over the forecast period to reach US $1.24 billion by 2027. IgE segment represented US $0.11 billion opportunity over 2019-2021 and estimated to create US $0.43 billion opportunity in 2027 over 2021.

IgD

IgD segment was valued at US $0.93 billion in 2019 and is projected to grow at 6.45% CAGR over the forecast period to reach US $1.63 billion by 2027. IgD segment represented US $0.14 billion opportunity over 2019-2021 and estimated to create US $0.56 billion opportunity in 2027 over 2021.

Mode of Delivery

Introduction

In 2021, Intravenous Mode of Delivery segment has the highest revenue of US $10.47 billion and is expected to grow at CAGR of 6.45% by 2027 Intravenous Mode of Delivery segment has highest cagr growth of 6.45%.

Intravenous Mode of Delivery

Intravenous Mode of Delivery segment was valued at US $9.09 billion in 2019 and is projected to grow at 6.45% CAGR over the forecast period to reach US $15.96 billion by 2027. Intravenous Mode of Delivery segment represented US $1.37 billion opportunity over 2019-2021 and estimated to create US $5.49 billion opportunity in 2027 over 2021.

Subcutaneous Mode of Delivery

Subcutaneous Mode of Delivery segment was valued at US $3.77 billion in 2019 and is projected to grow at 6.45% CAGR over the forecast period to reach US $6.61 billion by 2027. Subcutaneous Mode of Delivery segment represented US $0.57 billion opportunity over 2019-2021 and estimated to create US $2.28 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, Hypogammaglobulinemia segment has the highest revenue of US $6.15 billion and is expected to grow at CAGR of 6.45% by 2027 Hypogammaglobulinemia segment has highest cagr growth of 6.45%.

Hypogammaglobulinemia

Hypogammaglobulinemia segment was valued at US $5.34 billion in 2019 and is projected to grow at 6.45% CAGR over the forecast period to reach US $9.38 billion by 2027. Hypogammaglobulinemia segment represented US $0.81 billion opportunity over 2019-2021 and estimated to create US $3.23 billion opportunity in 2027 over 2021.

Chronic Inflammatory demyelinating polyneuropathy (CIDP)

Chronic Inflammatory demyelinating polyneuropathy (CIDP) segment was valued at US $3.46 billion in 2019 and is projected to grow at 6.45% CAGR over the forecast period to reach US $6.08 billion by 2027. Chronic Inflammatory demyelinating polyneuropathy (CIDP) segment represented US $0.52 billion opportunity over 2019-2021 and estimated to create US $2.09 billion opportunity in 2027 over 2021.

Immunodeficiency Disease

Immunodeficiency Disease segment was valued at US $1.92 billion in 2019 and is projected to grow at 6.45% CAGR over the forecast period to reach US $3.36 billion by 2027. Immunodeficiency Disease segment represented US $0.29 billion opportunity over 2019-2021 and estimated to create US $1.16 billion opportunity in 2027 over 2021.

Myasthenia Gravis

Myasthenia Gravis segment was valued at US $1.22 billion in 2019 and is projected to grow at 6.45% CAGR over the forecast period to reach US $2.14 billion by 2027. Myasthenia Gravis segment represented US $0.18 billion opportunity over 2019-2021 and estimated to create US $0.74 billion opportunity in 2027 over 2021.

Other Applications

Other Applications segment was valued at US $0.92 billion in 2019 and is projected to grow at 6.45% CAGR over the forecast period to reach US $1.62 billion by 2027. Other Applications segment represented US $0.14 billion opportunity over 2019-2021 and estimated to create US $0.56 billion opportunity in 2027 over 2021.